Skip to content

Study · Non-randomized trial · n = 8 · 1986

3 results

Vasoactive intestinal peptide as a bronchodilator in severe asthma.

Morice AH, Sever PS

Peptides1 Jan 1986Cited by 9 (Europe PMC)

PMID3529052 (opens in a new tab)DOI10.1016/0196-9781(86)90202-0 (opens in a new tab)PepBankPUB-03529052
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In inpatients recovering from severe acute asthma, VIP infusion significantly increased peak expiratory flow rate after 30 minutes.

    In plain wordsIn people recovering from a severe asthma attack, VIP infusion improved peak airflow.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePeak expiratory flow rate change
    Study

    n = 8

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    6 pmol/kg/min · intravenous · 30 minutesAs given in this study (human).

    Measurements

    PEFR increase
    26 l/min
    VIP 6 pmol/kg/min at 30 minutes

    Source sentences

    Summary
    VIP (6 pmol/kg/min) infusion caused significant (p less than 0.01) increase in peak expiratory flow rate (PEFR) of 26 +/- 9 (SEM) l/min after 30 minutes infusion compared with a bronchodilation of 39 +/- 19 l/min seen with salbutamol (5 mcg/min).
    1 context sentence
    Summary · context
    In two studies vasoactive intestinal peptide (VIP) was administered intravenously to two groups of eight in-patient volunteers recovering from severe acute asthma.
  2. 02HumanNon-randomized trialEfficacy outcome

    In inpatients recovering from severe acute asthma, the bronchodilation with VIP infusion was smaller than with salbutamol.

    In plain wordsIn people recovering from a severe asthma attack, VIP opened the airways less than salbutamol did.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePeak expiratory flow rate change compared with salbutamol
    Study

    n = 8

    Comparator
    Salbutamol
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    6 pmol/kg/min · intravenous · 30 minutesAs given in this study (human).

    Measurements

    PEFR increase
    26 l/min
    VIP 6 pmol/kg/min
    PEFR increase
    39 l/min
    salbutamol 5 mcg/min

    Source sentences

    Summary
    VIP (6 pmol/kg/min) infusion caused significant (p less than 0.01) increase in peak expiratory flow rate (PEFR) of 26 +/- 9 (SEM) l/min after 30 minutes infusion compared with a bronchodilation of 39 +/- 19 l/min seen with salbutamol (5 mcg/min).
    2 context sentences
    Summary · context
    VIP is a bronchodilator in severe asthma, although its effects are less than conventional medication.
    Summary · context
    In two studies vasoactive intestinal peptide (VIP) was administered intravenously to two groups of eight in-patient volunteers recovering from severe acute asthma.
  3. 03HumanNon-randomized trialEfficacy outcome

    In inpatients recovering from severe acute asthma, VIP infusion after nebulized ipratropium bromide caused significant bronchodilation.

    In plain wordsIn people recovering from a severe asthma attack, VIP infusion still opened the airways after ipratropium treatment.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseBronchodilation after ipratropium pretreatment
    Study

    n = 8

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Bronchodilation
    25 l/min
    VIP after nebulized ipratropium bromide

    Source sentences

    Summary
    Following pretreatment with nebulized ipratropium bromide, VIP infusion caused a significant (p less than 0.02) bronchodilation of 25 l/min.
    1 context sentence
    Summary · context
    In two studies vasoactive intestinal peptide (VIP) was administered intravenously to two groups of eight in-patient volunteers recovering from severe acute asthma.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.